Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV001241750 | SCV001414791 | likely benign | Cohen syndrome | 2024-01-22 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV003414049 | SCV004109399 | uncertain significance | VPS13B-related disorder | 2024-02-13 | criteria provided, single submitter | clinical testing | The VPS13B c.5528A>T variant is predicted to result in the amino acid substitution p.Glu1843Val. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.032% of alleles in individuals of African descent in gnomAD. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |
Ambry Genetics | RCV004034692 | SCV004978153 | uncertain significance | Inborn genetic diseases | 2023-12-21 | criteria provided, single submitter | clinical testing | The c.5603A>T (p.E1868V) alteration is located in exon 34 (coding exon 33) of the VPS13B gene. This alteration results from a A to T substitution at nucleotide position 5603, causing the glutamic acid (E) at amino acid position 1868 to be replaced by a valine (V). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Natera, |
RCV001241750 | SCV002082585 | uncertain significance | Cohen syndrome | 2020-02-13 | no assertion criteria provided | clinical testing |